Pyrimidine Triones as Potential Activators of p53 Mutants
Authors:
- Maryam M. Jebril FallatahMFMaryam M. Jebril Fallatah
- Özlem DemirÖDÖzlem Demir
- Fiona LawFLFiona Law
- Linda LauingerLLLinda Lauinger
- Roberta BaronioRBRoberta Baronio
- Linda HallLHLinda Hall
- Elodie BourniqueEBElodie Bournique
- Ambuj SrivastavaASAmbuj Srivastava
- Landon Tyler MetzenLMLandon Tyler Metzen
- Zane NormanZNZane Norman
- Rémi BuissonRBRémi Buisson
- Rommie E. AmaroRARommie E. Amaro
Open Access
- 8 August 2024
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 14 (8) , 967
Abstract
P53 is a crucial tumor suppressor in vertebrates that is frequently mutated in human cancers. Most mutations are missense mutations that render p53 inactive in suppressing tumor initiation and progression. Developing small-molecule drugs to convert mutant p53 into an active, wild-type-like conformation is a significant focus for personalized cancer therapy. Prior research indicates that reactivating p53 suppresses cancer cell proliferation and tumor growth in animal models. Early clinical evidence with a compound selectively targeting p53 mutants with substitutions of tyrosine 220 suggests potential therapeutic benefits of reactivating p53 in patients. This study identifies and examines the UCI-1001 compound series as a potential corrector for several p53 mutations. The findings indicate that UCI-1001 treatment in p53 mutant cancer cell lines inhibits growth and reinstates wild-type p53 activities, including DNA binding, target gene activation, and induction of cell death. Cellular thermal shift assays, conformation-specific immunofluorescence staining, and differential scanning fluorometry suggest that UCI-1001 interacts with and alters the conformation of mutant p53 in cancer cells. These initial results identify pyrimidine trione derivatives of the UCI-1001 series as candidates for p53 corrector drug development.Keywords
Funding Information
- National Computational Infrastructure (R21 CA267495-01, R01 CA271586-01, R37-CA252081, RSG-24-1249960-01-DMC, R01GM132826, CHE060073N)
- ACS (R21 CA267495-01, R01 CA271586-01, R37-CA252081, RSG-24-1249960-01-DMC, R01GM132826, CHE060073N)
- NIH (R21 CA267495-01, R01 CA271586-01, R37-CA252081, RSG-24-1249960-01-DMC, R01GM132826, CHE060073N)
- NSF (R21 CA267495-01, R01 CA271586-01, R37-CA252081, RSG-24-1249960-01-DMC, R01GM132826, CHE060073N)
- Saudi Arabian Cultural Mission (SACM) (R21 CA267495-01, R01 CA271586-01, R37-CA252081, RSG-24-1249960-01-DMC, R01GM132826, CHE060073N)
This publication has 72 references indexed in Scilit:
- Characterization of the generic mutant p53-rescue compounds in a broad range of assaysCancer Cell, 2024
- Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric SiteCancer Cell, 2021
- SLMP53-1 interacts with wild-type and mutant p53 DNA-binding domain and reactivates multiple hotspot mutationsBiochimica et Biophysica Acta (BBA) - General Subjects, 2020
- Allele-Specific p53 Mutant ReactivationCancer Cell, 2012
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core DomainCancer Cell, 2009
- The screening of the second‐site suppressor mutations of the common p53 mutantsInternational Journal of Cancer, 2007
- The IARC TP53 database: New online mutation analysis and recommendations to usersHuman Mutation, 2002
- The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53Cell, 1990
- Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.The EMBO Journal, 1990